Article

Treatment delay associated with alternative medicine use among veterans with head and neck cancer

Health Services Research and Development Center of Excellence, VA Puget Sound Health Care System, Seattle, Washington, USA.
Head & Neck (Impact Factor: 3.01). 10/2006; 28(10):926-31. DOI: 10.1002/hed.20420
Source: PubMed

ABSTRACT Use of complementary and alternative medicine (CAM) is increasing in the United States. This study investigates whether the use of alternative medicine is associated with a delay of treatment in head and neck cancer.
This study used the records obtained from a large trial involving ambulatory care US veterans. Subjects completed a CAM utilization questionnaire. The primary outcome variable was the time duration from cancer diagnosis to the time of cancer treatment.
Of veterans with head and neck cancer, 51% reported using some form of CAM, whereas 23% reported using a therapy classified as alternative medicine. Patients who used alternative medicine significantly delayed cancer treatment by 22 days compared with those who did not use alternative medicine (p = .05, 95% confidence interval [CI] = 0-44 days).
CAM use is common in veterans with head and neck cancer. Use of alternative medicine was associated with a significant delay in cancer treatment.

Download full-text

Full-text

Available from: Greg E Davis, Jun 27, 2015
0 Followers
 · 
154 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To assess whether complementary and alternative medicine (CAM) use is associated with the timing of highly active antiretroviral therapy (HAART) initiation among human immunodeficiency virus (HIV)-infected participants of the Women's Interagency HIV Study. Prospective cohort study between January 1996 and March 2002. Differences in the cumulative incidence of HAART initiation were compared between CAM users and non-CAM users using a logrank test. Cox regression model was used to assess associations of CAM exposures with time to HAART initiation. MAIN OUTCOME AND EXPOSURES: Study outcome was time from January 1996 to initiation of HAART. Primary exposure was use of any CAM modality before January 1996, and secondary exposures included the number and type of CAM modalities used (ingestible CAM medication, body practice, or spiritual healing) during the same period. One thousand thirty-four HIV-infected women contributed a total of 4987 person-visits during follow-up. At any time point, the cumulative incidence of HAART initiation among CAM users was higher than that among non-CAM users. After adjustment for potential confounders, those reporting CAM use were 1.34 times (95% confidence interval: 1.09, 1.64) more likely to initiate HAART than non-CAM users. Female CAM users initiated HAART regimens earlier than non-CAM users. Initiation of HAART is an important clinical marker, but more research is needed to elucidate the role specific CAM modalities play in HIV disease progression.
    Alternative therapies in health and medicine 14(5):18-22. · 1.14 Impact Factor
  • Trends in Pharmacological Sciences 03/2007; 28(2):48-50. DOI:10.1016/j.tips.2006.12.008 · 9.99 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background.The role of complementary and alternative medicine (CAM) in cancer treatment is controversial. The aim of the study was to assess whether CAM use was associated with a delay in the initiation of conventional cancer treatment for head and neck cancer.Methods.CAM usage data were collected by mailed questionnaire for 149 incident head and neck cancer patients who were identified through the Metropolitan Detroit Cancer Surveillance System. Time from cancer diagnosis to the start of conventional cancer treatment was analyzed by the Kaplan–Meier method.Results.Overall 79% of the subjects reported use of at least 1 of the CAM items asked in the questionnaire. The time to conventional cancer treatment did not differ by prior CAM use intended to treat cancer (p =.209).Conclusions.The results of the present registry-based study do not suggest that alternative therapy use in patients with head and neck cancer delays conventional cancer treatment. © 2007 Wiley Periodicals, Inc. Head Neck, 2008
    Head & Neck 04/2008; 30(4):446 - 454. DOI:10.1002/hed.20721 · 3.01 Impact Factor